Source: Annual Congress 2006 - Influenza: from avian flu to pandemia?
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. L. Johnston (London, United Kingdom). Antiviral drugs: which and when?. Annual Congress 2006 - Influenza: from avian flu to pandemia?

Member's Comments

No comment yet.

Related content which might interest you: Immunotherapy: when, who and which drug? Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Development of RSV antiviral treatment: where are we? Source: International Congress 2019 – Respiratory syncytial virus infections throughout life Year: 2019 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Optimising bronchodilator therapy in COPD: Who, why and when? Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care Year: 2019 Eradication and long-term antibiotic treatment: does it make sense? Source: International Congress 2014 – PG08 The management of non-CF bronchiectasis: from childhood to adulthood Year: 2014 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Pre-chemotherapy drug sensitivity test for antitubercular drugs in India – is it essential? Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Investigating the steroids and long-acting β2-agonists combination: why do we need more? Source: Eur Respir J 2004; 23: 501-502 Year: 2004 Management of COVID-19: Drugs anti-virals Source: ERS Course 2021 - COVID-19: State of the art Year: 2021 Direct - acting oral anticoagulants: which agent for which patient? Source: International Congress 2019 – Update on anticoagulant therapy: controversy and progress Year: 2019 Therapeutic strategies in pneumonia: going beyond antibiotics Source: Eur Respir Rev 2015; 24: 516-524 Year: 2015 Inhaled antibiotics: a new tool? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Targeting neuropetides: from antiemetics to bronchodilators? Source: Annual Congress 2012 - ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!" Year: 2012